# Bundibugyo Ebola vaccine trials

> Live situation record from CLSTR: https://clstr.news/situations/bundibugyo-ebola-vaccine-trials
> Updated: 2026-08-04T15:00:19.000Z. Sources: 20. Developments: 2.

In late July 2026, the Oxford Vaccine Group administered the first dose of its ChAdOx1 BDBV vaccine to a healthy British volunteer, marking the start of a Phase 1 safety and immunogenicity study. The adenoviral‑vector vaccine targets the Bundibugyo strain of Ebola, for which no licensed vaccine exists, and is backed by 600,000 doses produced by the Serum Institute of India in anticipation of successful results. The trial follows a worsening Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared a public‑health emergency with over 2,500 confirmed cases and 1,000 deaths.

A week later, Moderna began its own Phase 1 trial of the mRNA‑1469 vaccine in Canada, enrolling about 80 adults across three sites. The study, approved by Health Canada, aims to assess safety and immune response. Moderna’s effort is supported by CEPI, which has pledged up to $50 million for early testing and manufacturing, and the company plans to make at least 500,000 doses available to low‑ and middle‑income countries at access pricing if approved. Updated outbreak figures cite 3,748 confirmed cases and 1,657 deaths in the DRC, underscoring the urgent need for multiple vaccine candidates.

On 4 August 2026, the first volunteer in Moderna’s Canadian trial received the mRNA‑1469 dose in Truro, Nova Scotia, confirming the study’s launch at three locations—Truro, Halifax and Toronto. The trial proceeds alongside the Oxford vaccine effort, reflecting a rapid, multinational push to develop effective vaccines against the Bundibugyo Ebola strain amid a severe epidemic in Central Africa.

## Claims

- Health Canada cleared the early‑stage study. (corroborated by 10 sources)
- The trial will enroll about 80 healthy adults at three sites in Canada. (corroborated by 10 sources)
- The World Health Organization and Africa CDC have declared the outbreak a public‑health emergency. (corroborated by 10 sources)
- Moderna began its first human trial of an experimental vaccine against Bundibugyo ebolavirus. (corroborated by 5 sources)
- The vaccine candidate is called mRNA-1469. (corroborated by 5 sources)
- CEPI has pledged up to $50 million to fund the vaccine’s early testing and manufacturing. (corroborated by 5 sources)
- The Bundibugyo outbreak in the Democratic Republic of Congo has 3,748 confirmed cases and 1,657 deaths as of Aug 1, according to U.S. CDC data. (corroborated by 5 sources)
- Moderna plans to make at least 500,000 doses available to low‑ and middle‑income countries at access pricing if the vaccine is approved. (corroborated by 5 sources)

## Timeline

### 2026-08-04: Moderna launches Phase 1 Ebola vaccine trial in Canada

Moderna’s mRNA‑1469 Ebola vaccine begins a Health‑Canada‑approved Phase 1 trial in Canada, enrolling ~80 adults; CEPI funds $50 M, and 500k doses will be offered to low‑income nations if approved.

20 sources. https://clstr.news/cluster/moderna-launches-first-human-trial-of-bundibugyo-ebola-vaccine-in-canada

### 2026-07-26: Oxford Vaccine ChAdOx1 BDBV Administered to First Human Volunteer

Oxford’s ChAdOx1 BDBV Ebola vaccine was given to volunteer Ed Hunt, the first human test, targeting the Bundibugyo strain amid a DRC outbreak.

2 sources. https://clstr.news/cluster/oxford-vaccine-chadox1-bdbv-administered-to-first-human-volunteer

---
Cite as: Bundibugyo Ebola vaccine trials. CLSTR, https://clstr.news/situations/bundibugyo-ebola-vaccine-trials